Literature DB >> 27551115

Perils of the Pathologic Complete Response.

Brent S Rose1, Eric P Winer1, Harvey J Mamon1.   

Abstract

Mesh：

Year:  2016        PMID： 27551115     DOI： 10.1200/JCO.2016.68.1718

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].

Authors:  Mircea Dediu; Christoph Zielinski
Journal:  Breast Care (Basel)       Date:  2019-08-29       Impact factor: 2.860

2.  Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes.

Authors:  Christof Kaltenmeier; Alison Althans; Maria Mascara; Ibrahim Nassour; Sidrah Khan; Richard Hoehn; Amer Zureikat; Samer Tohme
Journal:  Am Surg       Date:  2020-12-19       Impact factor: 0.688

3.  Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Authors:  Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

4.  Analysis of delay in adjuvant chemotherapy in locally advanced rectal cancer.

Authors:  C A Farzaneh; A Pigazzi; W Q Duong; J C Carmichael; M J Stamos; F Dekhordi-Vakil; F Dayyani; J A Zell; M D Jafari
Journal:  Tech Coloproctol       Date:  2022-08-30       Impact factor: 3.699

Review 5.  A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.

Authors:  Mircea Dediu; Christoph Zielinski
Journal:  Breast Care (Basel)       Date:  2019-05-27       Impact factor: 2.860

6.  Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.

Authors:  Joohyun Woo; Se Jeong Oh; Jeong-Yoon Song; Byung Joo Chae; Jung Eun Choi; Jeeyeon Lee; Heung Kyu Park; Woosung Lim
Journal:  BMC Cancer       Date:  2021-05-31       Impact factor: 4.430

7.  The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers.

Authors:  Viriya Kaewkangsadan; Chandan Verma; Jennifer M Eremin; Gerard Cowley; Mohammad Ilyas; Sukchai Satthaporn; Oleg Eremin
Journal:  J Immunol Res       Date:  2017-08-23       Impact factor: 4.818

8.  Making progress in early breast cancer: Taking time or accepting risk?

Authors:  Gurdeep S Mannu; David Dodwell
Journal:  Eur J Cancer       Date:  2017-04-12       Impact factor: 9.162

Review 9.  Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

Authors:  Remco de Bree; Gregory T Wolf; Bart de Keizer; Iain J Nixon; Dana M Hartl; Arlene A Forastiere; Missak Haigentz; Alessandra Rinaldo; Juan P Rodrigo; Nabil F Saba; Carlos Suárez; Jan B Vermorken; Alfio Ferlito
Journal:  Head Neck       Date:  2017-08-17       Impact factor: 3.147

10.  Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Jean Schneider; Hyouk Jin Lee; Seok Jin Nam; Soo Jung Lee; Jin Hyang Jung; Sung Hoo Jung; Seung Taek Lim; Ye Won Jeon; Hongki Gwak
Journal:  J Breast Cancer       Date:  2020-05-12       Impact factor: 3.588
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.